Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2589 of 6351
-
Desperate patients get early access to experimental brain drug
Disease control Expanded access (ended)This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New imaging tool helps doctors see brain tumors more clearly
Diagnosis Expanded accessThe participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's…
Sponsor: St. Jude Children's Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Last-Resort drug access opens for rare sly syndrome patients
Disease control Expanded accessIndividual patient expanded access requests may be considered for patients who have no other treatment options
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope: early access to investigational drug for solid tumors
Disease control Expanded accessThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to telisotuzumab adizutecan prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug brensocatib offered to bronchiectasis patients who completed key trial
Disease control ApprovedThe purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Compassionate use of ritlecitinib offers hope for severe hair loss patients
Disease control Expanded accessProvide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Early access to promising cancer pill before official approval
Disease control Expanded accessThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential ben…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Last-Resort drug alpelisib made available for patients with no other options
Disease control Expanded accessThe purpose of this registration is to list Managed Access Programs (MAPs) related to BYL719, Alpelisib
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental drug offered to stem cell transplant patients with rare blood disorder
Disease control ApprovedThe purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.
Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug made available early for men with advanced prostate cancer
Disease control Expanded access (ended)The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).
Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug ABBV-706 made available for some lung cancer patients before approval
Disease control Expanded accessThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-706 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benef…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Last-Resort cell therapy offered to sarcoma patients
Disease control Expanded accessThe purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers w…
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New stem cell filter could make transplants safer for vulnerable patients
Disease control Expanded accessAllogeneic stem cell transplantation (alloSCT) is utilized for various underlying diseases. AlloSCT is limited by graft versus host disease (GVHD), graft rejection, viral infections, and post-transplant lymphoproliferative disorders. To mitigate graft versus host disease, graft m…
Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Last-Resort cancer vaccine made available for AML and MDS patients
Disease control Expanded accessSingle patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Last-Resort drug access opens for aggressive breast cancer patients
Disease control Expanded accessThis Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to participate in a clinical trial.
Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug access for low blood sugar after Weight-Loss surgery
Disease control Expanded accessThe Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program. The safety of avexitide and patient treatment experience will be monitored …
Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Aggressive chemo plus stem cell transplant tested for breast cancer
Disease control CompletedTo determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental device aims to tame disease without drugs
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could an unapproved device change medical care?
Knowledge-focused Details not publishedSponsor: [Redacted] • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC